Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure

C. J. Hannan, Y. Liang, Jerry David Allison, C. G. Pantazis, J. R. Searle

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Immune deficient mice growing xenografts of HT-29 or A-431 cell lines were treated with cisplatin carboplatin or doxorubicin in combination with one hour of wholebody pulsed magnetic field (PMF) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTesla(rms); pulses rose for 120 μsec and then abruptly fell to neutral and were repeated at a rate of 250 pulses per second). At 24 days the mice in each experiment were found to have significantly (p < 0.05 ANOVA) different tumor sizes among groups. The smallest mean tumor volume was consistently found in the drug + PMF group. With A-431 tumors the cisplatin + PMF group (T) was significantly smaller 52% [1-(100T/C)], than the cisplatin alone group (C). In HT-29 tumors, those treated with carboplatin + PMF had the smallest tumor volume at just 34% of the carboplatin-alone group. In HT-29 tumors, the doxorubicin + PMF group was 35% of the doxorubicin alone group.

Original languageEnglish (US)
Pages (from-to)1521-1524
Number of pages4
JournalAnticancer research
Volume14
Issue number4 A
StatePublished - Jan 1 1994

Fingerprint

Magnetic Fields
Heterografts
Carboplatin
Carcinoma
Drug Therapy
Doxorubicin
Cisplatin
Tumor Burden
Neoplasms
Analysis of Variance
Heart Rate
Cell Line
Pharmaceutical Preparations

Keywords

  • Carboplatin
  • Chemotherapy
  • Cisplatin
  • Doxorubicin
  • Experimental therapeutics
  • Pulsed magnetic field

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hannan, C. J., Liang, Y., Allison, J. D., Pantazis, C. G., & Searle, J. R. (1994). Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. Anticancer research, 14(4 A), 1521-1524.

Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. / Hannan, C. J.; Liang, Y.; Allison, Jerry David; Pantazis, C. G.; Searle, J. R.

In: Anticancer research, Vol. 14, No. 4 A, 01.01.1994, p. 1521-1524.

Research output: Contribution to journalArticle

Hannan, CJ, Liang, Y, Allison, JD, Pantazis, CG & Searle, JR 1994, 'Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure', Anticancer research, vol. 14, no. 4 A, pp. 1521-1524.
Hannan CJ, Liang Y, Allison JD, Pantazis CG, Searle JR. Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. Anticancer research. 1994 Jan 1;14(4 A):1521-1524.
Hannan, C. J. ; Liang, Y. ; Allison, Jerry David ; Pantazis, C. G. ; Searle, J. R. / Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. In: Anticancer research. 1994 ; Vol. 14, No. 4 A. pp. 1521-1524.
@article{7360bc7eabaa4d8f949b0a53084e38e3,
title = "Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure",
abstract = "Immune deficient mice growing xenografts of HT-29 or A-431 cell lines were treated with cisplatin carboplatin or doxorubicin in combination with one hour of wholebody pulsed magnetic field (PMF) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTesla(rms); pulses rose for 120 μsec and then abruptly fell to neutral and were repeated at a rate of 250 pulses per second). At 24 days the mice in each experiment were found to have significantly (p < 0.05 ANOVA) different tumor sizes among groups. The smallest mean tumor volume was consistently found in the drug + PMF group. With A-431 tumors the cisplatin + PMF group (T) was significantly smaller 52{\%} [1-(100T/C)], than the cisplatin alone group (C). In HT-29 tumors, those treated with carboplatin + PMF had the smallest tumor volume at just 34{\%} of the carboplatin-alone group. In HT-29 tumors, the doxorubicin + PMF group was 35{\%} of the doxorubicin alone group.",
keywords = "Carboplatin, Chemotherapy, Cisplatin, Doxorubicin, Experimental therapeutics, Pulsed magnetic field",
author = "Hannan, {C. J.} and Y. Liang and Allison, {Jerry David} and Pantazis, {C. G.} and Searle, {J. R.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "1521--1524",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 A",

}

TY - JOUR

T1 - Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure

AU - Hannan, C. J.

AU - Liang, Y.

AU - Allison, Jerry David

AU - Pantazis, C. G.

AU - Searle, J. R.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Immune deficient mice growing xenografts of HT-29 or A-431 cell lines were treated with cisplatin carboplatin or doxorubicin in combination with one hour of wholebody pulsed magnetic field (PMF) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTesla(rms); pulses rose for 120 μsec and then abruptly fell to neutral and were repeated at a rate of 250 pulses per second). At 24 days the mice in each experiment were found to have significantly (p < 0.05 ANOVA) different tumor sizes among groups. The smallest mean tumor volume was consistently found in the drug + PMF group. With A-431 tumors the cisplatin + PMF group (T) was significantly smaller 52% [1-(100T/C)], than the cisplatin alone group (C). In HT-29 tumors, those treated with carboplatin + PMF had the smallest tumor volume at just 34% of the carboplatin-alone group. In HT-29 tumors, the doxorubicin + PMF group was 35% of the doxorubicin alone group.

AB - Immune deficient mice growing xenografts of HT-29 or A-431 cell lines were treated with cisplatin carboplatin or doxorubicin in combination with one hour of wholebody pulsed magnetic field (PMF) exposure (calculated peak field 5.2 mTesla, with an average field strength of 0.525 mTesla(rms); pulses rose for 120 μsec and then abruptly fell to neutral and were repeated at a rate of 250 pulses per second). At 24 days the mice in each experiment were found to have significantly (p < 0.05 ANOVA) different tumor sizes among groups. The smallest mean tumor volume was consistently found in the drug + PMF group. With A-431 tumors the cisplatin + PMF group (T) was significantly smaller 52% [1-(100T/C)], than the cisplatin alone group (C). In HT-29 tumors, those treated with carboplatin + PMF had the smallest tumor volume at just 34% of the carboplatin-alone group. In HT-29 tumors, the doxorubicin + PMF group was 35% of the doxorubicin alone group.

KW - Carboplatin

KW - Chemotherapy

KW - Cisplatin

KW - Doxorubicin

KW - Experimental therapeutics

KW - Pulsed magnetic field

UR - http://www.scopus.com/inward/record.url?scp=0028073402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028073402&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1521

EP - 1524

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 A

ER -